Neal Shore, MD, FACS; Carolina Urologic Research Center 5Live #ASCO20
4:58
Key Insights on HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Genitourinary Malignancies
Neal Shore, MD, FACS; Carolina Urologic Research Center 5Live #ASCO20
Key Insights on HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Genitourinary Malignancies Similar Videos
Similar Videos
